Logo 1 Logo 2

Clinical Trial Details

Trial ID: L5903
Source ID: NCT05502562
Associated Drug: Oral Semaglutide
Title: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes in India
Acronym: PIONEER REAL
Status: COMPLETED
Study Results: NO
Results:
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG: Oral semaglutide
Outcome Measures: Primary: Change in Glycated haemoglobin A1c (HbA1c), Measured as percentage (%)-points., From baseline (week 0) to End of Study visit (V3) (week 34-44) | Secondary: Relative change in body weight, Measured in percentage (%)., From baseline (week 0) to End of Study visit (V3) (week 34-44)|Absolute change in body weight, Measured in kilogram (kg)., From baseline (week 0) to End of Study visit (V3) (week 34-44)|Glycated haemoglobin A1c (HbA1c) less than (<) 7%, Measured as Yes or No., At End of Study visit (V3) (week 34-44)|HbA1c reduction greater than or equal to (>=) 1%-points and body weight reduction of greater than or equal to (>=) 5%, Measured as Yes or No., From baseline (week 0) to End of Study visit (V3) (week 34-44)|HbA1c reduction greater than or equal to (>=) 1%-points and body weight reduction of greater than or equal to (>=) 3%, Measured as Yes or No., From baseline (week 0) to End of Study visit (V3) (week 34-44)
Sponsor/Collaborators: Sponsor: Novo Nordisk A/S
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases:
Enrollment: 388
Study Type: OBSERVATIONAL
Study Designs: Observational Model: |Time Perspective: p
Start Date: 2023-02-24
Completion Date: 2024-06-03
Results First Posted:
Last Update Posted: 2024-09-19
Locations:
URL: https://clinicaltrials.gov/show/NCT05502562